Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib + Chemo for Recurrent Cervical Cancer
NCT04188847Phase 2Completed
- Start
- Dec 2019
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in Cervical Cancer (CC). Primary endpoint: Overall Response Rate at 1 year. Started Dec 2019; status: completed.
02
Drugs
Rivoceranib
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT04188847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04188847.